Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 168-172

  D'Amico, Anthony V ^a   Whittington, Richard ^a   Malkowicz, S Bruce ^a   Fondurulia, Julie ^a   Chen, Ming Hui ^a   Kaplan, Irving ^a   Beard, Clair J ^a   Tomaszewski, John E ^a   Renshaw, Andrew A ^a   Wein, Alan ^a   Coleman, C Norman ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ANTIGEN DETECTION; ARTICLE; BEAM THERAPY; CANCER STAGING; CANCER SURVIVAL; HIGH RISK PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROSTATECTOMY;

EID: 0032951318     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.168     Document Type: Article

References (31)

1. Zagars GK, Pollack A, Kavadi VS, et al: Prostate specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-30, 1995
2. Pisansky TM, Kahn MJ, Rasp GM, et al: A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate cancer. Cancer 79:337-344, 1997
3. Lee WR, Hanks GE, Schultheiss TE, et al: Localized prostate cancer treated by external beam radiotherapy alone: Serum prostate specific antigen driven outcome analysis. J Clin Oncol 13:464-469, 1995
4. Pisansky TM, Cha SS, Earle JD, et al: Prostate specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol 11:2158-2166, 1993
5. Zietman AL, Coen JJ, Shipley WU, et al: Radical radiation therapy in the management of prostatic adenocarcinoma: The initial prostate specific antigen value as a predictor of treatment outcome. J Urol 151:640-645, 1994
6. Hanks GE, Lee WR, Schultheiss TE: Clinical and biochemical evidence of control of prostate cancer at 5 years after external beam radiation. J Urol 154:456-459, 1995
7. Partin AW, Piantadosi S, Sanda MG, et al: Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. Urology 45:831-838, 1995
8. Lerner SE, Blute ML, Bergstralh EJ, et al: Analysis of risk factors for progression in patients with pathologically organ confined prostate cancers after radical retropubic prostatectomy. J Urol 156:137-143, 1996
9. Zietman AL, Edelstein RA, Coen JJ, et al: Radical prostatectomy for adenocarcinoma of the prostate: The influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43:828-833, 1994
10. D'Amico AV, Whittington R, Malkowicz SB, et al: PSA failure despite pathologically organ confined and margin negative disease. The basis for an adjuvant therapy trial. J Clin Oncol 15:1465-1469, 1997
11. D'Amico AV, Whittington R, Malkowicz SB, et al: Outcome based staging for clinically localized adenocarcinoma of the prostate. J Urol 158:1422-1426, 1997
12. Partin AW, Kattan MW, Subong ENP, et al: Combination of prostate specific antigen, clinical stage, and Gleason score to predict pathologic stage of localized prostate cancer: A multi-institutional update. JAMA 277:1445-1451, 1997
13. Walsh PC, Partin AW, Epstein JI: Cancer control and quality of life following anatomical radical retropubic prostatectomy. Results at 10 years. J Urol 152:1831-1836, 1994
14. Kattan MW, Eastham JA, Stapleton AMF, et al: A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90:766-771, 1998
15. D'Amico AV, Whittington R, Malkowicz SB, et al: The combination of the preoperative prostate-specifics antigen level and postoperative pathologic findings to predict PSA outcome in men with chinically localized prostate cancer. J Urol (in press)
16. Partin AW, Pearson JD, Landis PK, et al: Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. Urology 43:649-659, 1994
17. Gleason DF, Veterans Administration Cooperative Urological Research Group: Histologic grading and staging of prostatic carcinoma, in Tannenbaum M (ed): Urologic Pathology. Philadelphia, PA, Lea & Febiger, 1997, pp 171-187
18. Beahrs OH, Henson DE, Hutter RVP, American Joint Committee on Cancer: Manual for Staging Cancer (ed 4). Philadelphia, PA, Lippencott, 1992
19. Oesterling JE, Jacobsen SJ, Klee GG, et al: Free, complexed and total serum prostate specific antigen: The establishment of approriate reference ranges for their concentrations and ratios. J Urol 154:1090-1095, 1995
20. Cox DR: Regression models and life tables. J R Stat Soc B 34:187-220, 1972
21. Efron R, Tibshirani R: An Introduction to the Bootstrap. New York, Chapman and Hall, 1993
22. Schemper M: The relative importance of prognostic factors in studies of survival. Stat Med 12:2377-2383, 1993
23. Ismail MT, Petersen RO, Alexander AA, et al: Tumor vascularity assessed by color Doppler imaging in prostate cancer: Prognostic implications. J Urol 159:288, 1998 (abstr 1110)
24. D'Amico AV, Whittington R, Tomaszewsk, JE, et al. A critical appraisal of the role of endorectal coil magnetic resonance imaging in the prediction of pathologic stage and postoperative prostate specific antigen failure in patients with clinically organ confined prostate cancer. J Clin Oncol 14:1770-1777, 1996
25. Yang RM, Naitoh J, Murphy M, et al: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol 159:941-945, 1998
26. Stapleton AM, Zbell P, Kattan MW, et al: Assessment of the biologic markers p53, Ki-67, and apoptotic index as predictive indicators of prostate carcinoma recurrence after surgery. Cancer 82:168-174, 1998
27. Waltregny D, de Leval L, Menard S, et al: Independent prognostic value of the 67-kd laminin receptor in human prostate cancer. J Natl Cancer Inst 89:1224-1227, 1997
28. Theodorescu D, Broder SR, Boyd JC, et al: Cathepsin D and chromogranin A as predictors of long term disease specific survival after radical prostatectomy for localized carcinoma of the prostate. Cancer 80:2109-2113, 1997
29. Snow PB, Levine RF, Ziada AM, et al: Impact of different variables on outcome of treatments for clinically confined prostate cancer: Prediction of response and pathological stage of the disease using a neural network. J Urol 159:295, 1998 (abstr 1136)
30. Cadeddu JA, Partin AW, Deweese TL, et al: Long-term results of radiation therapy for prostate cancer recurrence following radical prostatectomy. J Urol 159:173-176, 1998
31. Lee WR, Hanks GE, Hanlon A: Increasing prostate-specific antigen profile following definitive radiation therapy for localized prostate cancer: Clinical observations. J Clin Oncol 15:230-238, 1997